CN Patent

CN112004527B — 用于治疗肺部疾病的可吸入脂质体缓释组合物

Assigned to Yingbo Pharmaceutical Co ltd · Expires 2024-09-24 · 2y expired

What this patent protects

提供了一种用于治疗肺部疾病的脂质体缓释组合物。脂质体缓释组合物包含脂质体，脂质体包含经聚乙二醇(PEG)修饰的脂质并且包封酪氨酸激酶抑制剂。酪氨酸激酶抑制剂稳定地包埋在脂质体内，并且所得脂质体药物制剂可以气雾化或雾化，经由吸入给药。该气雾化的脂质体药物制剂产生一致的药代动力学和药效学特性，同时实现理想的药效和安全性。

USPTO Abstract

提供了一种用于治疗肺部疾病的脂质体缓释组合物。脂质体缓释组合物包含脂质体，脂质体包含经聚乙二醇(PEG)修饰的脂质并且包封酪氨酸激酶抑制剂。酪氨酸激酶抑制剂稳定地包埋在脂质体内，并且所得脂质体药物制剂可以气雾化或雾化，经由吸入给药。该气雾化的脂质体药物制剂产生一致的药代动力学和药效学特性，同时实现理想的药效和安全性。

Drugs covered by this patent

Patent Metadata

Patent number
CN112004527B
Jurisdiction
CN
Classification
—
Expires
2024-09-24
Drug substance claim
No
Drug product claim
No
Assignee
Yingbo Pharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.